These findings suggest that anti-BCMA-CAR3 T cells can produce cytokines and proteins in response to BCMA-expressing MM cells, which could potentially contribute to an anti-tumor immune response. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.